Background: The role of autosomal dominant polycystic kidney disease (ADPKD) as a risk factor for renal cell carcinoma (RCC) is still under discussion. Data on prevalence of RCC in ADPKD are limited, especially on a large population scale. The aim of this study was to analyze the prevalence of RCC in ADPKD kidneys and characterize the clinical features of this coincidence. Methods: Based on our histopathological registry for ADPKD and the Else Kröner-Fresenius Registry, we retrospectively reviewed malignant and benign renal lesions in patients with ADPKD who had undergone renal surgery from 1988 to 2011. Results: 240 ADPKD patients underwent 301 renal surgeries. Mean age at surgery was 54 years. Overall, 16 malignant and 11 benign lesions were analyzed in 301 kidneys (5.3%; 3.7%), meaning that 12/240 (5%; 1:20) patients presented with malignant renal lesions. 66.7% (8/12) of these patients had undergone dialysis prior to surgery. We found 10/16 (63%) papillary RCC, 5/16 (31%) clear cell RCC, and 1/16 (6%) papillary noninvasive urothelial cancer. Regarding all renal lesions, 6/17 (35.3%) patients had more than one histological finding in their kidneys. In 2 cases, metachronous metastases were removed. Mean follow-up was 66.7 months. Conclusion: Kidney-related prevalence of RCC in ADPKD kidneys was surprisingly high. Whether or not this is due to chronic dialysis or due to the underlying disease is still speculative. Like other cystic renal diseases with an increased risk for RCC, the attending physician should be aware of the malignant potential of ADPKD, especially with concomitant dialysis.

Keywords:
Adult polycystic renal disease, Renal cell carcinoma, Renal cell cancer, Autosomal dominant polycystic kidney disease
1.
Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-1301.
2.
Walters W, Braasch WF: Surgical aspect of polycystic kidney. Surg Obstet Gynecol 1934;647-650.
3.
Keith DS, Torres VE, King BF, Zincki H, Farrow GM: Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994;4:1661-1669.
4.
Miwa S, Fuse H, Hirano S, Masuda S: Transitional cell carcinoma of the renal pelvis in a long-term hemodialysis patient with autosomal dominant polycystic kidney. Int J Urol 2001;8:572-574.
5.
Hama Y, Kaji T, Ito K, Hayakawa M, Tobe M, Kosuda S: Erythropoietin-producing renal cell carcinoma arising from autosomal dominant polycystic kidney disease. Br J Radiol 2005;78:269-271.
6.
Chang YL, Chung HJ, Chen KK: Bilateral renal cell carcinoma in a patient with autosomal dominant polycystic kidney disease. J Chin Med Assoc 2007;70:403-405.
7.
Jurgensen JS, Muller V, Kettritz U, Woywodt A, Gobel U, Luft FC: A malignant ‘incidentaloma' in a patient with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999;14:490-492.
8.
Hajj P, Ferlicot S, Massoud W, Awad A, Hammoudi Y, Charpentier B, Durrbach A, Droupy S, Benoit G: Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology 2009;74:631-634.
9.
Lane W, Lacefield E, Tran R, Riese W: The clinical association of autosomal dominant polycystic kidney disease and renal cell carcinoma. Open J Urol 2011;2:11-14.
10.
Bernstein J, Evan AP, Gardner KD Jr: Human cystic kidney diseases: epithelial hyperplasia in the pathogenesis of cysts and tumors. Pediatr Nephrol 1987;1:393-396.
11.
Gregoire JR, Torres VE, Holley KE, Farrow GM: Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1987;9:27-38.
12.
Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E, Cronin K: SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute Bethesda, 2012. http://seercancergov/csr/1975_2009_pops09/.
13.
Orskov B, Sorensen VR, Feldt-Rasmussen B, Strandgaard S: Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2012;27:1607-1613.
14.
Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P: Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003;14:197-207.
15.
Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE: Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-2831.
16.
Shebl FM, Warren JL, Eggers PW, Engels EA: Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol 2012;13:65.
17.
Bonsib SM: Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc Nephrol 2009;4:1998-2007.
18.
Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, Dalrymple NC, Chintapalli KN: Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006;26:1795-1806.
19.
Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-624.
20.
Hughson MD, Buchwald D, Fox M: Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis. Arch Pathol Lab Med 1986;110:592-601.
21.
Ishikawa I, Kovacs G: High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 1993;22:135-139.
22.
DeLong MJ, Schmitt D, Scott KM, Ramakumar S, Lien YH: Multicentric papillary renal carcinoma in renal allograft. Am J Kidney Dis 2003;42:381-384.
23.
Neuzillet Y, Lay F, Luccioni A, Daniel L, Berland Y, Coulange C, Lechevallier E: De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer 2005;103:251-257.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.